ADHD Medication During Pregnancy and Breastfeeding
The decision to stop or continue ADHD medication during pregnancy and breastfeeding is a difficult decision for women suffering from the condition. There are few data regarding how exposure over time may affect the pregnant fetus.
A recent study published in Molecular Psychiatry shows that children exposed to ADHD medication in the uterus do not develop neurological disorders like impaired vision or hearing, febrile seizures, or IQ impairment. The authors acknowledge the need for higher-quality research.
Risk/Benefit Analysis
Women who are pregnant and taking ADHD medications must weigh the advantages of taking them against the potential risks to the foetus. Doctors don’t have the information needed to make unequivocal recommendations, but they can provide information about benefits and risks that can help pregnant women make informed decisions.
A study published in Molecular Psychiatry found that women who took ADHD medications during early pregnancy did not have an increased risk of fetal heart malformations or major birth defects that are structural. Researchers conducted a large population-based case-control study to evaluate the incidence of major structural birth defects in infants born to mothers who had taken stimulants during the early stages of pregnancy, and those who did not. Pediatric cardiologists, clinical geneticists and other experts reviewed the cases in order to confirm that the classification was correct and to minimize any bias.
However, the study was not without its flaws. The researchers were unable, in the first place to differentiate the effects of the medication from the disorder. That limitation makes it difficult to determine whether the small differences observed in the groups that were exposed result from medication use or the confounding effect of comorbidities. The researchers also did not study long-term outcomes for the offspring.
The study did find that babies whose mothers had taken ADHD medication during pregnancy were at slightly greater risk of being admitted to the neonatal intensive care unit (NICU) than infants whose mothers had not taken any medication or taken off their medication prior to or during pregnancy. This increase was caused by central nervous system disorders. The higher risk of admission was not affected by the stimulant medication that was used during pregnancy.
Women who were taking stimulant ADHD medications during pregnancy also had a higher risk of having to have a caesarean section or a baby that scored low on the Apgar scale (less than 7). These increases appear to be independent of the type of medication used during pregnancy.
Researchers suggest that the minor risks associated with the use ADHD medications during early pregnancies could be offset by the greater benefits to both mother and baby of continuing treatment for the woman’s condition. Doctors should discuss with their patients about this issue and, if possible, help them develop coping strategies that may reduce the effects of her disorder on her daily functioning and her relationships.
Interactions with Medication
Doctors are increasingly faced with the decision of whether to keep treatment or stop it during pregnancy as more women are diagnosed with ADHD. Most Popular Adhd Medication of the time, these decisions are taken in the absence of solid and reliable evidence regardless, so doctors have to weigh their experience from their own experiences, those of other doctors, and what research suggests about the subject, along with their own judgments for each patient.
The issue of potential risks for infants can be particularly tricky. The research on this issue is based on observation rather than controlled studies and many of the findings are conflicting. Most studies limit their analysis to live births, which may underestimate the severity of teratogenic effects which can a general practitioner prescribe adhd medication cause abortions or terminations of pregnancy. The study that is discussed in the journal club addresses these shortcomings, by examining both data on live and deceased births.
The conclusion is that while certain studies have demonstrated an association between ADHD medications and the possibility of certain birth defects, other studies have found no connection, and most studies demonstrate a neutral or slightly negative effect. As a result, a careful risk/benefit analysis must be conducted in every case.
It can be challenging, if not impossible, for women with ADHD to stop taking their medication. In a recent piece published in the Archives of Women’s Mental Health by psychologist Jennifer Russell, she notes that stopping adhd medication how does it work medications during pregnancy can cause depression and feelings of loneliness. A decrease in medication could also impact the ability to safely drive and perform work-related tasks, which are essential aspects of daily life for those suffering from best adhd medication for adults with anxiety.
She suggests that women who aren’t sure whether to take the medication or stop due to pregnancy educate family members, colleagues, and friends about the condition, the impact on daily functioning and the advantages of staying on the current treatment plan. Educating them can also make the woman feel more comfortable as she struggles with her decision. Some medications can pass through the placenta. If the patient decides not to take her ADHD medication while pregnant and breastfeeding, it’s important to be aware that the drug may be transferred to her infant.
Risk of Birth Defects
As the use and misuse of ADHD medication to treat symptoms of attention deficit hyperactivity disorder (ADHD), increases as does the concern about the potential adverse effects of the drugs on fetuses. A recent study published in the journal Molecular Psychiatry adds to the existing knowledge about this subject. Researchers used two huge datasets to analyze over 4.3 million pregnancies and determine whether stimulant medications increased birth defects. While the overall risk is low, the researchers found that exposure in the first trimester to ADHD medicines was associated with an increased risk of certain heart defects such as ventriculo-septal defect (VSD).
The researchers behind the study found no connection between the use of early medications and other congenital abnormalities, like facial clefting, or club foot. The results are in the same vein as previous studies that have shown an insignificant, but small increase in the number of cardiac malformations among women who began taking ADHD medication prior to the time of pregnancy. The risk was higher during the latter part of pregnancy, when a lot of women decide to stop taking their medication.
Women who took ADHD medications in the first trimester of their pregnancies were also more likely to undergo caesarean sections, a low Apgar score following delivery, and a baby who needed breathing assistance during birth. However the researchers of the study were not able to eliminate bias due to selection by restricting the study to women who did not have any other medical conditions that could be a contributing factor to these findings.
Researchers hope that their study will inform physicians when they see pregnant women. The researchers advise that, while discussing risks and benefits are important, the choice on whether to continue or stop medication should be made in light of the severity of each woman’s ADHD symptoms and the needs of the woman.
The authors also warn that even though stopping the medication is an alternative, it is not an option that is recommended due to the high prevalence of depression and other mental health problems among women who are pregnant or recently post-partum. Research has also shown that women who stop taking their medications used for adhd will have a harder transitioning to life without them after the baby is born.
Nursing
The responsibilities that come with being a new mother can be overwhelming. Women with ADHD who have to manage their symptoms while attending doctor appointments as well as getting ready for the arrival of a baby and adjusting to new household routines are often faced with a number of difficulties. Many women choose to continue taking their ADHD medication during pregnancy.
The majority of stimulant medications pass through breast milk in low amounts, so the risk to the breastfeeding infant is minimal. The rate of exposure to medication will differ based on dosage and frequency of administration as well as the time of day. Additionally, different medications are introduced into the baby’s system via the gastrointestinal tract, or through breast milk. The impact on the health of a newborn is not fully comprehended.
Because of the lack of evidence, some doctors might be tempted to stop taking stimulant drugs during a woman’s pregnancy. This is a difficult decision for the patient, who must balance the benefits of keeping her medication with the potential risks to the foetus. In the meantime, until more information is available, doctors may ask pregnant patients whether they have a background of ADHD or if they intend to take medication in the perinatal phase.
A increasing number of studies have shown that the majority of women are able to safely continue to take their ADHD medication while they are pregnant and nursing. In the end, many patients opt to do this and in consultation with their doctor they have found that the benefits of keeping their current medication exceed any risk.
It is essential for women with ADHD who are contemplating breastfeeding to seek a specialist psychiatrist’s advice prior becoming pregnant. They should discuss the medication they are taking with their physician, and the pros and cons for continuing treatment. This includes non-pharmacological methods. Psychoeducation is also necessary to help pregnant women suffering from ADHD recognize the signs and the underlying disorder. They should also be informed about treatment options and strengthen coping mechanisms. This should include an approach that is multidisciplinary, including the GP doctors, obstetricians and psychiatrists. Pregnancy counseling should include a discussion of a treatment plan for the mother and child, and monitoring for indicators of deterioration, and, if necessary, adjustments to the medication regime.